Form 4: Aligos Therapeutics Executive Julian A. Symons Reports Stock Option Grant

Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, reported the acquisition of stock options on March 1, 2024.

Summary

• On March 4, 2024, Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, filed a Form 4 with the SEC.
• The filing reports the grant of a stock option to purchase 72,000 shares of Aligos Therapeutics common stock.
• The exercise price of the stock option is $1.13.
• The options vest in 48 equal monthly installments starting March 1, 2024, and will be fully vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service.
• The expiration date for the options is March 1, 2034.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The granting of stock options to executives aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule of 4 years is typical for such grants, aligning executive incentives with long-term company performance.
• The size of the grant (72,000 shares) would need to be compared to grants made to executives with similar roles at comparable companies to determine if it is above or below industry standards.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the executive to work towards increasing shareholder value.

Key Dates